Mei Pharma Stock Analysis

MEIP Stock  USD 2.31  0.01  0.43%   
MEI Pharma is undervalued with Real Value of 6.68 and Target Price of 20.0. The main objective of MEI Pharma stock analysis is to determine its intrinsic value, which is an estimate of what MEI Pharma is worth, separate from its market price. There are two main types of MEI Pharma's stock analysis: fundamental analysis and technical analysis.
The MEI Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. MEI Pharma is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. MEI Stock trading window is adjusted to America/New York timezone.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MEI Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in MEI Stock, please use our How to Invest in MEI Pharma guide.

MEI Stock Analysis Notes

About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.71. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MEI Pharma recorded a loss per share of 5.73. The entity last dividend was issued on the 16th of November 2023. The firm had 1:20 split on the 17th of April 2023. MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Mei Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about MEI Pharma contact Justin CPA at 858 369 7100 or learn more at https://meipharma.com.

MEI Pharma Investment Alerts

MEI Pharma generated a negative expected return over the last 90 days
MEI Pharma has a very high chance of going through financial distress in the upcoming years
MEI Pharma currently holds about 153.25 M in cash with (50.47 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15.
Latest headline from finance.yahoo.com: Why PDD Holdings Inc. is a Cheap Internet Stock to Buy According to Hedge Funds

MEI Pharma Upcoming and Recent Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
24th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

MEI Largest EPS Surprises

Earnings surprises can significantly impact MEI Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-11-14
2022-09-30-0.14-0.120.0214 
2021-11-10
2021-09-30-0.13-0.110.0215 
2017-05-04
2017-03-31-0.04-0.020.0250 
View All Earnings Estimates

MEI Pharma Environmental, Social, and Governance (ESG) Scores

MEI Pharma's ESG score is a quantitative measure that evaluates MEI Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of MEI Pharma's operations that may have significant financial implications and affect MEI Pharma's stock price as well as guide investors towards more socially responsible investments.

MEI Pharma Thematic Classifications

In addition to having MEI Pharma stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products Idea
Pharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

MEI Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Dimensional Fund Advisors, Inc.2024-12-31
23.4 K
Susquehanna International Group, Llp2024-12-31
22.6 K
State Street Corp2024-12-31
17.8 K
Ubs Group Ag2024-12-31
11.2 K
Virtu Financial Llc2024-12-31
10.7 K
Morgan Stanley - Brokerage Accounts2024-12-31
5.8 K
Newbridge Financial Services Group, Inc.2024-12-31
K
Group One Trading, Lp2024-12-31
K
Tower Research Capital Llc2024-12-31
1.4 K
Anson Funds Management Lp2024-12-31
1.1 M
Cable Car Capital Llc2024-12-31
611.4 K
Note, although MEI Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

MEI Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.32 M.

MEI Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets 0.39  0.41 
Return On Capital Employed 0.40  0.42 
Return On Assets 0.39  0.41 
Return On Equity 0.48  0.51 

Management Efficiency

MEI Pharma has return on total asset (ROA) of (0.3068) % which means that it has lost $0.3068 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9368) %, meaning that it created substantial loss on money invested by shareholders. MEI Pharma's management efficiency ratios could be used to measure how well MEI Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/14/2025, Return On Tangible Assets is likely to grow to 0.41. Also, Return On Capital Employed is likely to grow to 0.42. At this time, MEI Pharma's Liabilities And Stockholders Equity is relatively stable compared to the past year. As of 03/14/2025, Non Current Liabilities Other is likely to grow to about 26.8 M, while Total Current Liabilities is likely to drop slightly above 8.3 M.
Last ReportedProjected for Next Year
Book Value Per Share 5.70  5.41 
Tangible Book Value Per Share 5.70  5.41 
Enterprise Value Over EBITDA 0.52  0.55 
Price Book Value Ratio 0.66  0.63 
Enterprise Value Multiple 0.52  0.55 
Price Fair Value 0.66  0.63 
Enterprise Value134.9 M141.7 M
The operational strategies employed by MEI Pharma management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta
0.633
Return On Assets
(0.31)
Return On Equity
(0.94)

Technical Drivers

As of the 14th of March 2025, MEI Pharma secures the mean deviation of 1.65, and Risk Adjusted Performance of (0.08). In connection with fundamental indicators, the technical analysis model lets you check helpful technical drivers of MEI Pharma, as well as the relationship between them.

MEI Pharma Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. MEI Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for MEI Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

MEI Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MEI Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on MEI Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MEI Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Anson Funds Management Lp over two weeks ago
Acquisition by Anson Funds Management Lp of 120000 shares of MEI Pharma at 6.0093 subject to Rule 16b-3
 
White Christine Anna over two months ago
Acquisition by White Christine Anna of 50000 shares of MEI Pharma at 2.95 subject to Rule 16b-3
 
Kango Sujay over three months ago
Acquisition by Kango Sujay of 87500 shares of MEI Pharma subject to Rule 16b-3
 
Richard Ghalie over six months ago
Disposition of tradable shares by Richard Ghalie of MEI Pharma subject to Rule 16b-3
 
Anson Funds Management Lp over six months ago
Disposition of 100 shares by Anson Funds Management Lp of MEI Pharma at 7.0 subject to Rule 16b-3
 
Howson Tamar D over six months ago
Acquisition by Howson Tamar D of 87500 shares of MEI Pharma subject to Rule 16b-3
 
Wood Steven D over six months ago
Acquisition by Wood Steven D of 3100 shares of MEI Pharma at 3.1701 subject to Rule 16b-3
 
Nicholas Glover over six months ago
Acquisition by Nicholas Glover of 87500 shares of MEI Pharma subject to Rule 16b-3
 
Funicular Funds, Lp over six months ago
Acquisition by Funicular Funds, Lp of 22400 shares of MEI Pharma at 6.4616 subject to Rule 16b-3
 
Thomas Reynolds over six months ago
Acquisition by Thomas Reynolds of 10000 shares of MEI Pharma at 7.01 subject to Rule 16b-3
 
Charles Baltic over six months ago
Acquisition by Charles Baltic of 81500 shares of MEI Pharma at 0.225 subject to Rule 16b-3
 
Wood Steven D over a year ago
Acquisition by Wood Steven D of 6700 shares of MEI Pharma subject to Rule 16b-3

MEI Pharma Outstanding Bonds

MEI Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MEI Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MEI bonds can be classified according to their maturity, which is the date when MEI Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

MEI Pharma Predictive Daily Indicators

MEI Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MEI Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

MEI Pharma Corporate Filings

8K
7th of March 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
12th of February 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
31st of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
20th of December 2024
Other Reports
ViewVerify
8K
25th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
14th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
12th of November 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
8K
25th of October 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

MEI Pharma Forecast Models

MEI Pharma's time-series forecasting models are one of many MEI Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MEI Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About MEI Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how MEI Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling MEI shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as MEI Pharma. By using and applying MEI Stock analysis, traders can create a robust methodology for identifying MEI entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.25  0.26 
Operating Profit Margin 0.20  0.21 
Net Profit Margin 0.25  0.26 
Gross Profit Margin 0.89  0.94 

Current MEI Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. MEI analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. MEI analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
20.0Hold2Odds
MEI Pharma current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most MEI analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand MEI stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of MEI Pharma, talking to its executives and customers, or listening to MEI conference calls.
MEI Analyst Advice Details

MEI Stock Analysis Indicators

MEI Pharma stock analysis indicators help investors evaluate how MEI Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading MEI Pharma shares will generate the highest return on investment. By understating and applying MEI Pharma stock analysis, traders can identify MEI Pharma position entry and exit signals to maximize returns.
Begin Period Cash Flow16.9 M
Total Stockholder Equity33 M
Property Plant And Equipment Net606 K
Cash And Short Term Investments38.3 M
Net Invested Capital33 M
Shares Float4.9 M
Cash3.7 M
200 Day M A2.8793
50 Day M A2.662
Net Interest Income3.3 M
Total Current Liabilities8.4 M
Investments49.1 M
Dividends Paid-11.7 M
Stock Based Compensation2.3 M
Common Stock Shares Outstanding6.7 M
Free Cash Flow-50.5 M
Operating Income14.5 M
Other Current Assets2.4 M
Accounts Payable3.2 M
Net Debt-3.7 M
Depreciation383 K
Other Operating Expenses50.8 M
Non Current Assets Total606 K
Liabilities And Stockholders Equity41.4 M
Home CategoryDomestic

Additional Tools for MEI Stock Analysis

When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.